Volume 20, Number 5—May 2014
Linezolid-Resistant Staphylococcus epidermidis, Portugal, 2012
To the Editor: Linezolid is a therapeutic option for skin and soft tissue infections and pneumonia caused by multidrug-resistant gram-positive bacteria (e.g., Staphylococcus spp.), which occur at higher rates in Portugal than in other European countries (www.ecdc.europa.eu/en/publications/Publications/annual-epidemiological-report-2013.pdf). Staphylococcus epidermidis are skin and mucosal commensal bacteria; infections in humans are mostly linked to indwelling medical devices. The ability of S. epidermidis to acquire resistance to antimicrobial drugs and to produce biofilm can seriously compromise the success of therapy; in many institutions worldwide, rates of methicillin resistance are >70% (1). Rates of S. epidermidis linezolid resistance on various continents have been low and are associated with mutations in the central loop of 23S rRNA V domain or ribosomal proteins (L3, L4, and L22) and with acquisition of the cfr gene, which codifies for ribosomal methyltransferase (1–3).
To our knowledge, in Portugal only 1 linezolid-resistant S. epidermidis isolate, from a dog with severe otitis, has been described (4). We report nosocomial emergence of methicillin- and linezolid-resistant S. epidermidis in Portugal.
We characterized 5 linezolid-resistant Staphylococcus isolates recovered during May–November 2012 from blood and catheters of patients in 4 wards of a 362-bed hospital in central Portugal. The origin of 1 isolate is unknown. Epidemiologic features are described in the Table. The patients had received linezolid during the present (n = 2 patients) or previous (n = 2 patients) hospitalizations, suggesting that the latter 2 patients could have been colonized with linezolid-resistant strains when discharged from the first hospitalization. Information about receipt of linezolid was not available for 1 patient.
S. epidermidis was identified by using a Vitek II system (bioMérieux, Marcy L’Étoile, France), and susceptibility to antimicrobial drugs was studied by using agar dilution (linezolid, vancomycin) or disk diffusion (another 10 drugs; Table) (5). All isolates were screened by PCR and sequenced for the cfr gene and for mutations in the 23S rRNA V domain and in genes (rplC, rplD and rplV) encoding the L3, L4, and L22 ribosomal proteins (6–8). Clonal relatedness was determined by pulsed-field gel electrophoresis (macrorestriction with SmaI) and by multilocus sequence typing (www.cdc.gov/hai/pdfs/labsettings/ar_mras_pfge_s_aureus.pdf and http://sepidermidis.mlst.net). S. epidermidis from patient 1 was searched for in vitro adherence to abiotic surfaces by using a biomass quantification assay (9) and strain ICE9 as a positive control.
All S. epidermidis isolates were resistant to multiple drugs, including linezolid (MIC>32 mg/L), cefoxitin, chloramphenicol, cotrimoxazole, ciprofloxacin, clindamycin, and aminoglycosides, and susceptible to only 4 drugs tested, including vancomycin (MIC = 2 mg/L) (Table). To characterize linezolid resistance, we compared the study isolates with linezolid-susceptible S. epidermidis RP62A/American Type Culture Collection 35984 sequence (GenBank accession no. CP000029). Study isolates contained the mutations T2530A, T2504A, and G2631T, although T2504A and G2631T were also present in linezolid-susceptible S. epidermidis RP62A (1,2). The most commonly reported G2576T mutation was not detected (1,2). We also compared study isolates with S. epidermidis RP62A and observed nucleotide mutations consistent with L94V (L101V from S. epidermidis American Type Culture Collection 12228, not associated with linezolid resistance) and G152D amino acid changes (2,8) and amino acid changes in the new D159E and A160P in L3 ribosomal protein. Mutations in this protein were linked to linezolid resistance, although definitive conclusions are not available (8). The cfr gene and mutations in ribosomal proteins L4 or L22 were not detected in the study isolates.
All isolates recovered had the same pulsed-field gel electrophoresis type and belonged to sequence type (ST) 2/clonal complex (CC) 5 (ST2 formerly belonged to CC2) (10) also detected among linezolid-resistant S. epidermidis from Europe, Brazil, and the United States (1–3). S. epidermidis from patient 1, considered representative of the observed clone, revealed a high ability to adhere to abiotic surfaces and grow in the biofilm form, which can facilitate infections associated with indwelling medical devices. This strain was classified as strongly adherent and had higher optical density (OD570nm = 2.33 ± 0.34) than a blank sample (culture medium: Luria Bertani broth + glucose; OD570nm = 0.2 ± 0.03). The OD570nm of the positive-control was 2.69 ± 0.44.
S. epidermidis ST2/CC5 is disseminated in hospital settings worldwide and is characterized by a high level of genetic diversity, an increased recombination/mutation rate, biofilm production ability, and acquisition of a high number of staphylococcal cassette chromosome mec elements (10). In Portugal, S. epidermidis ST2/CC5 has been observed in the community (10). We report emergence of methicillin- and linezolid-resistant S. epidermidis in a hospital in Portugal and its persistence for at least 7 months. Identification of the successful multidrug-resistant S. epidermidis ST2/CC5 clonal lineage highlights the need for strict infection control procedures and revision of therapeutic strategies (e.g., linezolid use for the treatment of methicillin-resistant Staphylococcus spp. only when vancomycin is not a treatment option because of elevated MIC or clinical failures) to preserve therapeutic effectiveness of linezolid. Effective control of linezolid-resistant S. epidermidis, including among hospital-discharged patients who had received linezolid, is critical for preventing the potential for an epidemic in this hospital, and, on a larger scale, in Portugal, as has occurred for other gram-positive methicillin-resistant S. aureus and vancomycin-resistant enterococci.
We thank Conceição Faria, Sofia Almeida, and other members of the Serviço de Patologia Clínica do Centro Hospitalar da Cova da Beira (Covilhã, Portugal), who kindly provided the linezolid-resistant S. epidermidis.
This project was funded by a research grant from the Fundação para a Ciência e Tecnologia (PEst-C/EQB/LA0006/2011). R.B. is supported by a PhD fellowship of the Fundação para a Ciência e Tecnologia (grant no. SFRH/BD/61410/2009).
- Mendes RE, Deshpande LM, Costello AJ, Farrell DJ. Molecular epidemiology of Staphylococcus epidermidis clinical isolates from U.S. hospitals. Antimicrob Agents Chemother. 2012;56:4656–61 .
- de Almeida LM, Lincopan N, Araújo MR, Mamizuka EM. Dissemination of the linezolid-resistant Staphylococcus epidermidis clone ST2 exhibiting the G2576T mutation in the 23S rRNA gene in a tertiary-care hospital, Brazil. J Antimicrob Chemother. 2012;67:768–9.
- Liakopoulos A, Spiliopoulou I, Damani A, Kanellopoulou M, Schoina S, Papafragas E, Dissemination of two international linezolid-resistant Staphylococcus epidermidis clones in Greek hospitals. J Antimicrob Chemother. 2010;65:1070–1 .
- Seixas R, Monteiro V, Carneiro C, Vilela CL, Oliveira M. First report of a linezolid-resistant MRSA (methicillin resistant Staphylococcus aureus) isolated from a dog with a severe bilateral otitis in Portugal. Revista Veterinaria. 2011;22:81–4.
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twentieth informational supplement M100–S21. Wayne (PA): The Institute; 2010.
- Kehrenberg C, Schwarz S. Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates. Antimicrob Agents Chemother. 2006;50:1156–63.
- Toh SM, Xiong L, Arias CA, Villegas MV, Lolans K, Quinn J, Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol. 2007;64:1506–14.
- Locke JB, Hilgers M, Shaw KJ. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob Agents Chemother. 2009;53:5265–74.
- Novais A, Pires J, Ferreira H, Costa L, Montenegro C, Vuotto C, Characterization of globally spread Escherichia coli ST131 isolates (1991 to 2010). Antimicrob Agents Chemother. 2012;56:3973–6.
- Rolo J, Lencastre H, Miragaia M. Strategies of adaptation of Staphylococcus epidermidis to hospital and community: amplification and diversification of SCCmec. J Antimicrob Chemother. 2012;67:1333–41.
- Table. Epidemiologic features and antimicrobial drug resistance of linezolid -resistant Staphylococcus epidermidis isolates from a hospital, Portugal, 2012
Suggested citation for this article: Barros M, Branquinho R, Grosso F, Peixe L, Novais C. Linezolid-resistant Staphylococcus epidermidis, Portugal, 2012 [letter]. Emerg Infect Dis [Internet]. 2014 May [date cited]. http://dx.doi.org/10.3201/eid2005.130783
Please use the form below to submit correspondence to the authors or contact them at the following address:
Carla Novais, Laboratório de Microbiologia. Faculdade de Farmácia da Universidade do Porto, Rua Jorge Viterbo Ferreira nº 228, 4050-313 Porto, PortugalCarla Novais, Laboratório de Microbiologia. Faculdade de Farmácia da Universidade do Porto, Rua Jorge Viterbo Ferreira nº 228, 4050-313 Porto, Portugal
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: April 17, 2014
- Page last updated: April 17, 2014
- Page last reviewed: April 17, 2014
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)